Memantine Synthesis via Controlled Acid-Formamide Reaction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for manufacturing N-Formyl-1-amino-3,5-dimethyladamantane and its subsequent conversion to Memantine hydrochloride involve hazardous chemicals, generate significant waste, and are not economically viable on an industrial scale due to the use of large excess reagents and halogenated solvents, along with the need for additional purification steps.

Innovation Solution

A process involving the reaction of 1,3-dimethyladamantane with a mixture of concentrated sulfuric and nitric acid, followed by formamide, with controlled molar ratios and temperatures, to produce N-Formyl-1-amino-3,5-dimethyladamantane, minimizing waste and avoiding halogenation steps, and subsequently converting it to Memantine hydrochloride without additional purification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If large excess of formamide, sulfuric acid, and nitric acid are used, then the reaction proceeds completely, but considerable waste is generated and disposal costs increase

Engineering Contradiction:
Improvereaction completenessVSAvoidchemical waste
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The patent changes the concentration parameters of reagents, using concentrated sulfuric acid (96-98%) and concentrated nitric acid (65-70%) instead of dilute solutions, which reduces the total volume and amount of reagents needed while maintaining reaction effectiveness

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies partial excess action by using only a small excess of formamide (1.05-1.20 equivalents) rather than large excess, and uses controlled amounts of acids (0.5-2.0 equivalents each) to achieve sufficient reaction conversion while minimizing waste generation

Inventive Principle:
Principle #16Partial or excessive action

2Manufacturing precision

If halogenated organic solvents are used for extraction, then the product can be separated from the mixture, but the process becomes economically unviable on industrial scale

Engineering Contradiction:
Improveproduct separationVSAvoidindustrial scalability
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent extracts and eliminates halogenated organic solvents from the process by using water as the extraction medium instead, which is much more economical and environmentally friendly for industrial-scale operations

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces expensive halogenated solvents with cheap water for extraction purposes, making the process economically viable on industrial scale while still achieving effective product separation

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Manufacturing precision

If additional purification step by chromatography is performed, then product purity is improved, but the process complexity and cost increase

Engineering Contradiction:
Improveproduct purityVSAvoidprocess complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent performs preliminary action by optimizing the reaction conditions and extraction process to obtain sufficiently pure product directly, eliminating the need for additional chromatography purification steps

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent removes the chromatography purification step from the process by using water extraction that directly yields product of sufficient purity for pharmaceutical applications

Inventive Principle:
Principle #2Taking out (Extraction)

4Productivity

If elemental chlorine or bromine is used for halogenation, then the synthesis follows the conventional pathway, but hazardous and toxic reagents are employed

Engineering Contradiction:
Improvesynthesis efficiencyVSAvoidtoxicity
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful halogenation step into a beneficial direct formylation reaction using formamide and acid catalyst, eliminating toxic halogen reagents while maintaining synthesis efficiency

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent inverts the conventional synthesis pathway by going directly from 1,3-dimethyladamantane to N-formyl-1-amino-3,5-dimethyladamantane without the halogenation intermediate, effectively reversing the traditional approach to avoid toxic reagents

Inventive Principle:
Principle #13The other way round (Inversion)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This process reduces the use of hazardous chemicals, minimizes waste, and enhances yield and selectivity, making it suitable for industrial-scale production while achieving high purity and compliance with pharmaceutical specifications.

Implementation Method 1

reacting 1,3-dimethyladamantane with an acid mixture comprising concentrated sulfuric acid and concentrated nitric acid

Methodology Applied
Scientific EffectElectrophilic substitution: Chemical Bonding

Implementation Method 2

reacting the solution from step (a) with an amount of formamide varying from 1 to 5 molar equivalents per mole of deprotonated 1,3-dimethyladamantane from step (a) to obtain N-Formyl-1-amino-3,5-dimethyladamantane

Methodology Applied
Scientific EffectNucleophilic addition: Chemical Bonding

Implementation Method 3

in step (b) the temperature is at least 50°C. In accordance with a further embodiment, said temperature is between 50-65°C

Methodology Applied
Scientific EffectThermal heating: Heating

Data Source

PatentEP2274276B1Process for the manufacture of memantine and intermediate product
Publication Date: 2014.07.09 MERZ PHARMA GMBH & CO KGAA
  • EP2274276B1 patent drawingFigure 1
  • EP2274276B1 patent drawingFigure 2
  • EP2274276B1 patent drawing

AI summary

The present invention relates to a process for manufacturing N-Formyl-1-amino-3,5-dimethyladamantane, an intermediate product in the overall process of producing 1-Amino-3,5-dimethyladamantane hydrochloride (Memantine). Therein, the process comprises the following steps: (a) reacting 1,3-dimethyladamantane with an acid mixture comprising concentrated sulfuric acid and concentrated nitric acid, wherein 1 to 6 volume parts of sulfuric acid (measured in ml) are used per weight part of 1,3-dimethyladamantane (measured in g); (b) reacting the solution from step (a) with an amount of formamide varying from 1 to 5 molar equivalents per mole of deprotonated 1,3-dimethyladamantane from step (a) to obtain N-Formyl-1-amino-3,5-dimethyladamantane. In step (b), the molar ratio of total acid, i.e. the molar amount of sulfuric acid and the molar amount of nitric acid taken together versus the molar amount of formamide is at least 1.5 and that the temperature is at least 5O0C. The present invention also relates to the overall process of manufacturing Memantine from 1,3-dimethyladamantane by means of hydrolyzing the intermediate NFORM.